Find Funding Opportunities

NIH Extramural Response to Natural Disasters and Other Emergencies

In emergency situations, the NIH’s immediate concern is for the health and safety of people and animals in the programs we oversee.  Visit the NIH Extramural Response to Natural Disasters and Other Emergencies web page for biomedical research community resources, including NIH Guide Notices and other information of particular relevance to investigators and their institutions, links to web pages listing NIH’s response to certain major events (past and present); and links to similar web sites from other Federal agencies.

 COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements

All NINDS-related notices of funding opportunities (NOFOs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed. Search the Closed Opportunities tab to find expired opportunities. Search the Notices tab to find all Notices.

Learn more about award types and program directors and managers.

NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!

For more focused results add quotes to indicate parameters. Example format: "search term".

Displaying 11 - 20 of 132 Open Funding Opportunities
NIH Research Education Program - Research Experiences (Parent R25 - Clinical Trial Not Allowed)
Expiration Date: Sunday, May 6, 2029
NOFO Number: PA-27-036
Monday, June 8, 2026
Notice Type: PA
The National Institutes of Health (NIH) Research Education Program supports research education activities in the mission areas of the NIH. The overarching goal of the Research Education program is to:Support educational activities that complement and/or enhance training of a workforce to meet the nation's biomedical, behavioral and clinical research needs;Help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences; and Foster a better understanding of biomedical, behavioral and clinical research and its implications.
BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS): Specialized Projects for Scalable Technologies (U01 Clinical Trial Not Allowed)
Expiration Date: Tuesday, October 5, 2027
NOFO Number: RFA-NS-27-015
Thursday, May 28, 2026
Notice Type: RFA
This funding announcement, issued by the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative, seeks transformative, cutting-edge, and innovative research that embraces new technologies, ideas, and approaches to understand brain circuit function and contributions to behavior. It is a component of the BRAIN Initiative Connectivity Across Scales (BRAIN CONNECTS) Program, which aims to lay the scientific foundation for the next generation of neural circuit-based approaches for preventing and treating devastating brain disorders.This Notice of Funding Opportunity (NOFO) supports Specialized Projects to develop current or emerging technologies to generate comprehensive atlases of brain connectivity, with an emphasis on human, non-human primate (NHP), and mouse. Projects using other species are also permitted, if their use is well justified and the goal is to test and validate approaches that can be generalized across species. Applications may address any aspect(s) of brain connectivity and associated data pipelines, including data collection, reconstruction, analysis, integration, dissemination, and interpretation, to enable faster, more precise, and more cost-effective generation and interpretation of brain-wide wiring diagrams. Funded projects will be integrated into the BRAIN CONNECTS Network consisting of projects funded under this and preceding BRAIN CONNECTS NOFOs, as a coordinated effort aimed at developing the capabilities to generate wiring diagrams that can span entire brains across multiple scales.
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Expiration Date: Tuesday, April 6, 2027
NOFO Number: PA-27-100
Thursday, May 28, 2026
Notice Type: PA
The Small Business Innovation Research (SBIR) program helps United States small business concerns (SBCs) bring scientific innovations to the marketplace. The SBIR program supports feasibility studies to later research and development (R&D) needed to develop a commercial product.
NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
Expiration Date: Friday, April 6, 2029
NOFO Number: PA-27-101
Thursday, May 28, 2026
Notice Type: PA
The NIH Phase IIB Strategic Breakthrough award bridges the funding gap between the end of a Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase II award and commercialization. The Phase IIB Strategic Breakthrough provides previously funded NIH SBIR or STTR projects additional support for later-stage research and development (R&D).
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Expiration Date: Tuesday, April 6, 2027
NOFO Number: PA-27-102
Thursday, May 28, 2026
Notice Type: PA
The Small Business Technology Transfer (STTR) grant program helps United States small business concerns (SBCs) that partner with a nonprofit research institution bring scientific innovations to the marketplace. The STTR program supports feasibility studies to later stage research and development (R&D) needed to develop a commercial product.
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Expiration Date: Friday, April 6, 2029
NOFO Number: PAR-27-098
Thursday, May 28, 2026
Notice Type: PAR
The Commercialization Readiness Pilot (CRP) program helps small business concerns (SBCs) move NIH-funded SBIR or STTR projects from late-stage development to commercialization. The CRP supports later-stage research and development (R&D) and/or technical assistance that Phase II and Phase IIB Strategic Breakthrough awards do not typically support. This includes:Independent replication or confirmation of key studiesIND- or IDE-enabling studiesClinical studiesManufacturing scale-up and related quality activitiesRegulatory and other specialized technical supportSBCs may subcontract (outsource) a significant amount of the work in a CRP to meet the project goals.
Maximizing the Scientific Value of Data Generated by the Environmental Influences on Child Health Outcomes (ECHO) Program: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)
Expiration Date: Thursday, December 3, 2026
NOFO Number: RFA-OD-27-008
Thursday, May 28, 2026
Notice Type: RFA
This NOFO seeks to advance research and training in high-priority areas of child health by stimulating the use of Environmental Influences on Child Health Outcomes (ECHO) Cohort data by postdoctoral fellows from relevant scientific disciplines. This RFA will provide opportunities for fellows to study child health outcomes through the analysis of ECHO's large longitudinal data sets within the NICHD Data and Specimen Hub (DASH) repository. ECHO's DASH dataset integrates de-identified longitudinal data from more than 71,000 participants across the U.S. Prenatal and child exposure data include physical, chemical, social, behavioral, and biological factors. ECHO's five primary pediatric outcome areas are pre-, peri-, and postnatal outcomes, upper and lower airway, obesity, neurodevelopment, and positive health.
Academic Career Excellence (ACE) Award (K32 Independent Clinical Trial Not Allowed)
Expiration Date: Friday, July 13, 2029
NOFO Number: PAR-27-062
Wednesday, May 27, 2026
Notice Type: PAR
The purpose of the Academic Career Excellence (ACE) Award (K32) is to support rigorous, mentored scientific research and career development for up to three years for early-stage postdoctoral scholars. Candidates must submit their application up to one year prior to beginning their postdoctoral position or no more than two years after their postdoctoral training begins (resubmissions included). The ACE K32 will foster early, goal-directed planning and encourage innovative applications with the potential for a significant impact on scientific research and career development. Inclusion of preliminary data are not required as the ACE K32 emphasizes innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral scholars who have the potential to become productive, independent investigators in research fields relevant to the missions of the participating NIH Institutes and Centers.
Limited Competition: Instrumentation Grant Program for Resource-Limited Institutions (S10 - Clinical Trial Not Allowed)
Expiration Date: Saturday, January 27, 2029
NOFO Number: PAR-27-067
Wednesday, May 27, 2026
Notice Type: PAR
The Instrumentation Grant Program for Resource-Limited Institutions supports the purchase of state-of-the-art scientific instruments to enhance the research and educational missions of resource-limited institutions. Requested instruments may support biomedical research and education in basic, translational, biomedically-related behavioral or clinical fields. This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
Expiration Date: Wednesday, November 11, 2026
NOFO Number: RFA-NS-26-001
Monday, May 4, 2026
Notice Type: RFA
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.